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A Quick Diversity-Oriented Amide-Forming
Reaction to Optimize P-Subsite Residues
of HIV Protease Inhibitors
and the by-products are often either difficult to separate
or interfere with the assay. There are a few reactions
(e.g., oxime formation, cycloaddtition reaction, and am-
ide bond formation) known to be rapid, chemoselective,
highly quantitative, free of protecting group, and com-
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The Scripps Research Institute patible with aqueous solution. Of such reactions, the
products, in principle, may be used in situ for screening10550 North Torrey Pines Road
La Jolla, California 9203 without concentration and purification. This strategy has
not been used effectively in drug discovery, however.
To illustrate the effectiveness of this approach, we have
selected the human immunodeficiency virus proteaseSummary
(HIV-1 PR) as our target, using a diversity-oriented am-
ide-forming reaction coupled with in situ screening.We report a new simple method that allows rapid prep-
Since the early days of the discovery of HIV-1 PR, thisaration in solution of a library of compounds for in situ
enzyme has been selected as an important target forhigh-throughput screening to identify new inhibitors
the inhibition of viral replication. The enormous effortof HIV-1 protease. The method is based on the amide-
over the past two decades to develop effective mole-forming reaction of a C2-symmetrical diamino diol core
cules that inhibit the HIV-1 PR has resulted in the discov-with various carboxylic acids, followed by a direct
ery of drugs that have dramatically improved the qualityassay of the inhibition activity without product isola-
of life and survival of patients infected with HIV-1. Totion. Sixty-two compounds were made and screened
date, there are six different HIV-1 PR inhibitors (PI) thatin less than 1 hr. The utility of this method is demon-
are commercially available (Figure 1) [1–3]. Unfortu-strated by the identification of new P3-P3 residues
nately, many drug-resistant and cross-resistant mutantthat convert a transition state analog core from a poor
HIV-1 PRs have been identified, rendering AIDS withbinding molecule (1, Ki  2 M) to a potent inhibitor
no definitive cure [4, 5]. Thus, the development of new(AB1, Ki  2 nM) against the wild-type, and the inhibi-
protease inhibitors which are efficacious against bothtion activities against resistant mutants are better than
the wild-type and drug-resistant HIV-1 PR and lessthose of two existing drugs. This method reduces the
prone to development of resistant strains of HIV is ur-time required for synthesis and testing of a large num-
gently needed.ber of characterized inhibitors and should find useful
Most of the P2-P2 and P3-P3 residues in the struc-applications in other enzyme systems.
ture of FDA-approved HIV-1 protease inhibitors were
attached to the cores through an amide bond (Figure
Introduction 1), making the amide bond-forming reaction of great
interest if one wishes to prepare and rapidly screen
Most of the drug discovery processes start with efforts inhibitors with new P-P residues (Figure 2). A vast
to identify lead compounds, either by screening chemi- amount of information is available regarding this chem-
cal libraries or natural products. Lead optimization is istry, both in solution and on solid support [6]. Several
then pursued through analog synthesis. In most cases, activation reagents in different solvents have been found
the basic structure unit of the lead compound is kept to give a quantitative yield in very short reaction time.
constant, while other parts of the molecule are modified For example, analogs of phosphonium salts, in particular
to generate a library. High-throughput screening is often N-[(1-H-benzotriazole-1-y) (dimethylamino) methylene]-
used in both lead identification and lead optimization. N-methylmethanaminium hexafluorophosphate N-oxide
A key to the success of this discovery process is effi- (HBTU) and N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]
ciency: formation of the expected product must be effi- pyridin-1-yl-methylene]-N-methylmethanaminium hexa-
cient, with high product purity and high yields. Ideally, fluorophosphate N-oxide (HATU), have been found to
the diversification process should be short, if possible be very efficient and convenient reagents to activate
a one-step reaction, and requires no further purification carboxylic acids for coupling [6].
before screening. Herein, we report a useful method that allows rapid
Solid-phase and solution-phase syntheses have been preparation of a library of inhibitors for in situ high-
used widely and successfully in lead identification and throughput screening to identify new HIV-1 PR inhibi-
lead optimization in drug discovery. The processes often tors. Once a new inhibitor is identified, it will be synthe-
depend on preparation of individual compound or mix- sized followed by more careful characterization using
ture, which are separated from the reaction reagents traditional methods. The new method is based on our
before biological assays. As a result, the chemistry is observation that the reaction conditions for attaching
often slower than the screening process. Though mix- various P-P residues using the amide-forming reaction
tures have been used for screening, they are often gen- between the C2-symmetrical diamino diol core and dif-
erated through multistep time-consuming processes, ferent carboxylic acids do not interfere with the HIV-1
PR inhibitor assay. The reaction is fast (30 min) and
gives the products in quantitative yields. The utility of3 Correspondence: wong@scripps.edu
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Figure 1. FDA-Approved HIV-1 Protease In-
hibitors, Showing the Site of the Attachment
of Different P2-P2 and P3-P3
our method is demonstrated by the identification of new thylamine was used as the basic core for the synthesis of
inhibitors. Most commonly, various P-P residues wereP-P residues that convert the core from a poor binding
molecule (Ki  2 M) to a potent inhibitor (Ki  2 nM), attached to the basic cores to form the active molecules.
It was found that subtle changes of the structure ofand the inhibition activities against resistant mutants
are better than those of two existing drugs. these residues could lead to new inhibitors with unique
binding interaction that are effective against drug-resis-
tant strains. For example, changing the tetrahydrofuranResults and Discussion
ring to bis–tetrahydrofyranyl urethane in Amprenavir has
furnished an extremely potent inhibitor, UIC-94003All commercially available drugs for HIV-1 PR and some
(TMC-126), that is effective against a wide spectrum ofof the inhibitors currently being tested clinically were
HIV strains [7]. Although solid-phase synthesis has beendeveloped based on the transition-state mimic concept,
used successfully to diversify several cores usingin which nonhydrolyzable hydroxyethylene or hydroxye-
multistep reactions [8–10], finding a method that would
allow easier, faster diversification and screening would
be highly valuable.
Our previous effort toward the development of prote-
ase inhibitors efficacious against both HIV and FIV was
focused on the systematic analysis of S3-S3 subsite
Figure 2. Principle of the Amide Bond-Forming Reaction to Gener-
ate a Library of HIV PR Inhibitors, Coupled with High-Throughput Figure 3. In Situ Preparation and Screening of Different Inhibitors
with Various P3-P3 ResiduesScreening
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Figure 4. Structure of the 61 Acids that Were Tested as Potential P3-P3 Residues
specificities of the enzymes using a series of C2-sym- reacted with various acids in solution, and the products
were screened for inhibition activity without any purifica-metric inhibitors containing (1S, 2R, 3R, 4S)-1,4-dia-
mino-1,4-dibenzyl-2,3-butan-diol 1a as a P1-P1 core tion (Figure 3). This idea was first tested on our previous
inhibitor TL-3 [13, 14] (Figure 5). The core 1a was reactedand Val as P2-P2 residues [11–14]. Several inhibitors
were synthesized and tested, including a variety of with Cbz-Ala (2.2 eq) in the presence of HBTU or HATU
(2.2 eq) and N, N-Disopropylethyl amine (DIEA) (4.4 eq)amino acids with different N-protecting group at the
P3-P3positions. Although various inhibitors were found in DMF or DMSO. The reaction product was diluted with
buffer and directly screened for its inhibition activity toto have high potency against HIV-1 PR in vitro, the evalu-
ations of other residues at these positions is a tedious give very similar results in terms of IC50 (5 nM) as
compared to the pure compound. Indeed, we haveprocess and is restricted by the time required for the
syntheses and purification of the new compounds for found that up to 200 M concentration of HBTU/HATU
and DIEA does not interfere with the activity of the HIV-1testing.
To overcome the above limitations, the C2-symmetri- PR. Further investigation of this reaction with various
acids revealed that all of reactions went to completioncal diaminodiol 1a and diamino alcohol 1b cores were
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Table 1. Percent Inhibition of HIV-1 Protease Activity at 100 nM of Product Generated by the Amide-Forming Reaction and In Situ Screening
after 30 min, as monitored by thin-layer chromatography
(TLC) and electrospray ionization mass spectrometry
(ESI-MS). In addition, the measured IC50 for the crude
Table 2. IC50 Values for Selected Acids at P3-P3 Positions products were nearly identical to the purified com-
Entry R-COOH IC50 (nM) pounds.
1 6 17
2 7 10
3 8 14
4 22 19
5 23 50
6 24 10
7 25 10
8 44 6  0.5
9 53 20
10 54 50
11 55 50
12 56 10
13 59 10
14 60 50
15 61 50
16 62 10
Assays were performed directly from reaction mixture after reac-
tions went to completion. For entry 8, IC50 was determined for the
pure compound. For each IC50 determination, assays were per-
formed in triplicate at five inhibitor concentrations.
Figure 5. Structure of AB-1 and TL-3
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The above results have encouraged us to prepare a amines for in situ screening to optimize the other P-P
residues.library of inhibitors by modifying the core structure 1a
with different P3-P3 residues. Initially, 50 different acids
(2–51, Figure 4) were analyzed in the same manner as
Significancedescribed. The acids were chosen based on availability,
cost, and diversity. Each carboxylic acid was added to
We have developed a simple method to rapidly preparea 200 l well of a 96 microtiter plate containing HBTU
a library of potential inhibitors in solution which areand DIEA in DMF followed by addition of core 1a, and
used directly without purification in a high-throughputthe mixture was kept at room temperature for 30 min.
screening to identify new P3-P3 residues for the HIV-The reaction mixture in each well was diluted to a final
PR. The method relies on the efficient, flexible, andconcentration of 100 nM, based on complete conversion
mild amide-forming reaction, and new inhibitors betterof the starting material to product, and screened for
than existing drugs against resistant mutants haveHIV-1 PR inhibition (Table 1). Wells that inhibited more
been rapidly identified within an hour. Although wethan 50% of the HIV-1 PR activity were diluted to 10 nM
have demonstrated the usefulness of this method toand screened again. We were able to carry out the whole
screen for new P3-P3 residues in HIV protease inhibi-process of activation, coupling, and in situ screening in
tors, it is also possible to use this strategy to identifyless than 1 hr.
other new residues in HIV PR inhibitors or other en-Several amide products from the acids attached to
zyme inhibitors.core 1a (Ki  2 M) were found to be very potent inhibi-
tors (Table 2). Some of the acids that formed strong
Experimental Proceduresinhibitors have been previously used before (e.g., 24) as
the P3 residue [1]. However, new residues at the P3-P3
General
positions also have emerged using our method, most Analytical TLC was performed on precoated plates (Merck, silica
notably acid 44 [5-(4-nitrophenyl)-2-furic acid] (Figure gel 60F-254). Silica gel used for flash column chromatography was
4), which furnished the potent inhibitor AB1 with IC50  Mallinckrodt Type 60 (230–400 mesh). Reagents of the highest purity
were purchased from the Aldrich, Sigma, Acros, Novabiochem, or10 nM for the crude compound (Figure 5). Further syn-
Bachem.thesis and characterization of this inhibitor on a large
scale allowed the determination of the IC50 and Ki of the
General Procedure for Coupling Reactionspure compound to be 6 nM and 2 nM, respectively. We
and In Situ Screeningalso tested compound AB1 against some of the resistant
Twenty microliters of each carboxylic acid (from a 100 mM stockprotease mutants, and the IC50 values against G48V and solution in DMF, 0.0022 mmol) was added to a 200 l well of a 96
V82F were found to be 23 nM and 16 nM, respectively, microtiter plate that contained 20 l of HBTU (from 100 mM stock
compared to 110 nM and 30 nM with the existing drug solution in anhydrous DMF, 1.1 eq), DIEA (0.0044 mmol). To each
saquniavir and 25 nM and 35 nM with nelfinavir. reaction mixture was added 10 l of the diaminodiol core 1 (from a
stock solution of 100 mM, 0.001 mmol in anhydrous DMF). All theWith this approach, it is also possible to design a
reactions were mixed once all the reagents were added and keptlibrary for structure activity relationship (SAR) studies.
at room temperature. The reactions went to completion in 30 min,For example, once we determined 44 to be a good P3-
based on the disappearance of the free amine monitored by TLC
P3 residue, we screened a series of acids that are struc- (10:1,CHCl3: MeOH, Rf  0.28) and analysis of the crude reaction
turally related to 44 (52–62, Figure 4). Analysis of the mixture by ESI-MS. The reaction mixture in each well was diluted
inhibition data shows that separation of the substitution to a final concentration of 100 nM into second 200 l wells of 96
microtiter plate using 0.1 M Mes buffer containing 0.2 M NaCl, 1by methylene group from the furan ring causes a loss
mM DTT (200 l final volume). To each well was added enzyme (30of activity (Entry 14 and 15, Table 2). Perhaps conjuga-
g/ml) and substrate (5 mM), and the wells were directly assayedtion of the two aromatic rings is important. In addition,
for HIV PR inhibition. Wells that inhibited more than 50% of the
we have found that the number and the position of the HIV-1 PR activity were diluted to 10 nM and screened again.
substitutions on the phenyl ring are important for the
inhibitor potency (Entry 9, 10, and 11, Table 2). Changing
Synthesis of AB1the nitro substitution on the para-position to the chloro
Diaminodiol core 1a was prepared as previously reported [14]. To
derivative seems to have a small effect on the inhibitor a solution of a free amine 1a (10 mg, 0.02 mmol) and 5-(4-nitrophe-
activity [Entry 16, Table 2]. We also have found that nyl)-2-furic acid (10 mg, 0.04 mmol) in 3 ml dry DMF was added
reacting the core 1b instead of 1a with various acids (7, HBTU (16 mg, 0.04 mmol) followed by DIEA (10 l, 0.08 mmol) at
20C under Ar atmosphere. The reaction mixture was stirred for 3014, 44, 53, and Cbz-Ala, Figure 4) have provided inhibi-
min and then quenched by addition of brine and extracted withtors that exhibited 1- to 2-fold decrease in IC50. These
EtOAc. The organic layer was washed with 1 N HCl, saturated aque-results are in agreement with the previous studies using
ous NaHCO3, and brine, dried over MgSO4, filtered, and concen-compounds obtained via traditional solution-phase and trated in vacuo. The crude product was purified by flash chromatog-
solid-phase syntheses [10, 15]. raphy (CHCl3: MeOH) to give the desired product in 90% yield (16
In summary, we have applied the amide-forming reac- mg). []25D  	13.0 (C  1, in DMSO) 1H NMR (400 MHZ, DMSO-d6)

 0.75 (d, 6.7 Hz, 6H), 0.83 (d, 6.5 Hz, 6H), 2.0 (m, 2H), 2.55 (m, 2H),tion in solution to generate libraries for in situ identifica-
2.73 (m, 2H), 3.16 (d, 5.2 Hz, 2H), 4.20 (t, 8.8 Hz 2H), 4.30 (m, 2H),tion of new P3-P3 residues. Sixty-two acids were acti-
4.80 (bs, 2H), 6.9 (m, 2H), 7.0 (t, 7.63 Hz, 4H) 7.15 (d, 11 Hz, 4H),vated, coupled to the amine core, and screened directly
7.36 (d, 3.5 Hz, 2H), 7.45 (d, 3.5 Hz, 2H), 7.55 (d, 9.3 Hz, 2H), 8.16for their inhibition activity in less than 1 hr. In principle,
(d, 9.12 Hz, 4H), 8.23 (d, 8.8 Hz, 2H), 8.33 (d, 8.8 Hz, 4H); 13C NMR
using other amine core or acid intermediates (e.g., in (400 MHZ, DMSO-d6) 
 170.1, 157.0, 152.2, 148.4, 146.7, 138.9, 135.1,
the case of Indinavir [16]), one can rapidly generate 129.1, 127.6, 125.5, 125.1, 124.3, 116.3, 111.6, 73.4, 58.6, 50.9, 29.5,
19.4, 18.7; ESI-MS, calc MH	 for (C50H52N6O12) 929.4, found 929.6.libraries of amides from libraries of various acids or
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